• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Reports First Quarter 2023 Financial Results; Quarterly Revenue of $106.1M Represents 23.5% Year-Over-Year Growth

    5/2/23 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    YOKNEAM, Israel, May 2, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2023.

    InMode_Logo

    First Quarter 2023 Highlights:

    • Quarterly revenue of $106.1 million, an increase of 23.5% compared to the first quarter of 2022. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 83% of quarterly revenues, while 8% came from InMode's hands-free platforms and 9% from InMode's traditional laser and non-invasive RF platforms.
    • GAAP net income of $40.5 million, compared to $31 million in the first quarter of 2022; *non-GAAP net income of $44.7 million, compared to $34.1 million in the first quarter of 2022.
    • GAAP diluted earnings per share of $0.47, compared to $0.36 in the first quarter of 2022; *non-GAAP diluted earnings per share of $0.52, compared to $0.40 in the first quarter of 2022.
    • Record quarterly revenues from consumables and service of $20 million, an increase of 43% compared to the first quarter of 2022.
    • Total cash position of $574.5 million as of March 31, 2023, including cash and cash equivalents, marketable securities, and short-term bank deposits.

     

    U.S. GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q1 2023

    Q1 2022

    Revenues

    $106,074

    $85,921

    Gross Margins

    83 %

    83 %

    Net Income

    $40,505

    $30,975

    Earnings per Diluted Share

    $0.47

    $0.36

    *Non-GAAP Results

    (U.S. dollars in thousands, except for per share data)



     Q1 2023

    Q1 2022

    Gross Margins

    83 %

    83 %

    Net Income

    $44,714

    $34,069

    Earnings per Diluted Share

    $0.52

    $0.40

    *Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation adjustments.

    Management Comments

    "As we celebrate the 15th anniversary of the founding of our company, we are pleased to report a strong start to 2023, driven by growing demand for InMode's procedures. Our unique technology enables patients to achieve effective surgical results while benefiting of minimally invasive procedures," said Moshe Mizrahy, Chairman and Chief Executive Officer.

    Shakil Lakhani, President of InMode North America, commented, "During the first quarter, we experienced significant growth in consumable sales. Revenue from consumables and service for the first quarter grew nearly 43% year-over-year. This is a strong indication that the platforms we sell are being used more frequently as the demand for our treatments continues to increase." 

    "We have seen an influx of patients seeking treatment following the use of popular weight loss drugs. InMode's technology can effectively assist patients in tightening the loose skin post the effects of these medications," said Dr. Spero Theodorou, Chief Medical Officer.

    First Quarter 2023 Financial Results

    Total revenues for the first quarter of 2023 reached $106.1 million, an increase of 23.5% compared to the first quarter of 2022.

    "We are happy to report substantial growth in Q1, while maintaining strong gross margins in what is traditionally a slower quarter for the aesthetics space. International sales were once again robust in the first quarter, with sales from Europe hitting a new record," said Yair Malca, Chief Financial Officer.

    GAAP gross margin for the first quarter of 2023 and 2022 was 83%. *Non-GAAP gross margin for the first quarter of 2023 and 2022 was 83%.

    GAAP operating margin for the first quarter of 2023 was 39%, compared to an operating margin of 41% in the first quarter of 2022. *Non-GAAP operating margin for the first quarter of 2023 was 43% compared to 44% for the first quarter of 2022. This slight decrease was primarily attributable to higher sales and marketing expenses, mainly as a result of the addition of new sales representatives as well as investment in direct-to-consumer advertising campaigns and hosting in-person events to support the company's growth projections.

    InMode reported GAAP net income of $40.5 million, or $0.47 per diluted share, in the first quarter of 2023, compared to $31 million, or $0.36 per diluted share, in the first quarter of 2022. On a *non-GAAP basis, InMode reported net income of $44.7 million, or $0.52 per diluted share, in the first quarter of 2023, compared to $34.1 million, or $0.40 per diluted share, in the first quarter of 2022.

    2023 Financial Outlook

    Management provided an outlook for the full year of 2023 ending December 31, 2023. Based on current estimates, management expects:

    • Revenue between $525 million and $530 million
    • *Non-GAAP gross margin between 83% and 85%
    • *Non-GAAP income from operations between $236 million and $238 million
    • *Non-GAAP earnings per diluted share between $2.58 and $2.60

    This outlook is not a guarantee of future performance and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.

    *Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation adjustments.

    Use of Non-GAAP Financial Measures

    In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, and non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.

    Conference Call Information

    Mr. Moshe Mizrahy, Chairman and Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer, Mr. Shakil Lakhani, President of North America, and Dr. Spero Theodorou, Chief Medical Officer, will host a conference call today, May 2, 2023, at 8:30 a.m. Eastern Time to discuss the first quarter 2023 financial results.

    The Company encourages participants to pre-register for the conference call using the following link: 

    https://dpregister.com/sreg/10177454/f8f5b01f02.

    Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

    For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

    U.S. Toll-Free Dial-in Number: 1-833-316-0562

    Israel Toll- Free Dial-in Number: 1-80-921-2373

    International Dial-in Number: 1-412-317-5736

    Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=frYtrZ1j

    At:

    8:30 a.m. Eastern Time

    5:30 a.m. Pacific Time

    3:30 p.m. Israel Time

    The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from May 2, 2023, at 12 p.m. Eastern Time to May 16, 2023, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

    Replay Dial-in U.S TOLL-FREE: 1-877-344-7529

    Replay Dial-in Canada TOLL-FREE: 855-669-9658

    Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088

    Replay Pin Number: 6947972

    To access the replay using an international dial-in number, please select the link below:

    https://services.choruscall.com/ccforms/replay.html

    A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.

    About InMode

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

    Forward-Looking Statements

    The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the future performance described above under the heading titled "2023 Financial Outlook." Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including with respect to the impact of the COVID-19 global outbreak. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 14, 2023, as well as risk factors relating to the COVID-19 global outbreak and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

    Company Contact:

    Yair Malca

    Chief Financial Officer

    Phone: (949) 305-0108

    Email: [email protected]

    Investor Relations Contact:

    Miri Segal

    MS-IR LLC

    Phone: (917) 607-8654

    Email: [email protected]

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    Three months ended

    M
    arch 31,



    2023

    2022

    REVENUES

    106,074

    85,921

    COST OF REVENUES

    18,254

    14,772

    GROSS PROFIT

    87,820

    71,149

    OPERATING EXPENSES:





    Research and development

    3,102

    2,815

    Sales and marketing

    41,713

    30,849

    General and administrative

    2,008

    2,477

    TOTAL OPERATING EXPENSES

    46,823

    36,141

    INCOME FROM OPERATIONS

    40,997

    35,008

    Finance income, net

    3,289

    379

    INCOME BEFORE TAXES

    44,286

    35,387

    INCOME TAXES

    3,781

    4,412

    NET INCOME

    40,505

    30,975







    NET INCOME PER SHARE:





    Basic

    0.49

    0.37

    Diluted

    0.47

    0.36

    WEIGHTED AVERAGE NUMBER OF SHARES

    OUTSTANDING USED IN COMPUTATION OF NET

    INCOME PER SHARE (in thousands)





    Basic

    83,154

    82,973

    Diluted

    85,387

    85,696

     

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    March 31,

    2023

    December 31,

    2022

    Assets





    CURRENT ASSETS:





    Cash and cash equivalents

    92,961

    97,540

    Marketable securities

    405,674

    374,589

    Short-term bank deposits

    75,817

    75,254

    Accounts receivable, net of allowance for doubtful accounts

    24,868

    26,997

    Other receivables

    14,802

    15,094

    Inventories

    40,811

    39,897

    TOTAL CURRENT ASSETS

    654,933

    629,371

    NON-CURRENT ASSETS:





    Accounts receivable

    3,883

    3,973

    Deferred income tax asset, net

    2,457

    3,094

    Operating lease right-of-use assets

    5,288

    5,073

    Property and equipment, net

    2,451

    2,298

    Other investments

    600

    600

    TOTAL NON-CURRENT ASSETS

    14,679

    15,038

    TOTAL ASSETS

    669,612

    644,409

    Liabilities and shareholders' equity





    CURRENT LIABILITIES:





    Accounts payable

    11,987

    16,242

    Contract liabilities

    17,293

    13,798

    Other liabilities

    30,391

    51,980

    TOTAL CURRENT LIABILITIES

    59,671

    82,020

    NON-CURRENT LIABILITIES:





    Contract liabilities

    3,042

    3,959

    Other liabilities

    391

    303

    Operating lease liabilities

    3,529

    3,509

    TOTAL NON-CURRENT LIABILITIES

    6,962

    7,771

    TOTAL LIABILITIES

    66,633

    89,791







    TOTAL SHAREHOLDERS' EQUITY

    602,979

    554,618

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

    669,612

    644,409

     

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended

    March 31,



    2023

    2022

    CASH FLOWS FROM OPERATING ACTIVITIES:





    Net income

    40,505

    30,975

    Adjustments required to reconcile net income to net cash

    provided by operating activities:





    Depreciation and amortization

    188

    138

    Share-based compensation expenses

    4,209

    3,094

    Change in allowance for credit losses of trade receivable

    (22)

    210

    Loss on marketable securities, net

    -

    14

    Finance expenses (income), net

    (1,512)

    90

    Deferred income taxes, net

    19

    (22)

    Changes in operating assets and liabilities:





    Decrease in accounts receivable

    2,241

    3,953

    Increase in other receivables

    (229)

    (1,195)

    Increase in inventories

    (914)

    (4,074)

    Increase (decrease) in accounts payable

    (4,255)

    762

    Decrease in other liabilities

    (23,043)

    (4,875)

    Increase in contract liabilities

    3,926

    2,783

    Net cash provided by operating activities

    21,113

    31,853

    CASH FLOWS FROM INVESTING ACTIVITIES:





    Investment in short-term deposits

    (6,000)

    (23,111)

    Proceeds from short-term deposits

    6,000

    20,000

    Purchase of fixed assets

    (341)

    (299)

    Purchase of marketable securities

    (118,352)

    (21,209)

    Proceeds from sale of marketable securities

    -

    994

    Proceeds from maturity of marketable securities

    91,137

    10,933

    Net cash used in investing activities

    (27,556)

    (12,692)

    CASH FLOWS FROM FINANCING ACTIVITIES:





    Repurchase of ordinary shares

    -

    (42,637)

    Exercise of options

    1,673

    161

    Net cash provided by (used in) financing activities

    1,673

    (42,476)

    EFFECT OF EXCHANGE RATE CHANGES ON CASH

    191

    (151)

    NET DECREASE IN CASH AND CASH EQUIVALENTS

    (4,579)

     

    (23,466)

    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

    97,540

    68,136

    CASH AND CASH EQUIVALENTS AT END OF PERIOD

    92,961

    44,670

     

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    Three months ended

    M
    arch 31,

    2023

    2022

    Revenues by Category:























    Capital Equipment revenues - United States

    49,751

    47 %

    44,760

    52 %



    Capital Equipment revenues - International

    36,373

    34 %

    27,183

    32 %



    Total Capital Equipment revenues

    86,124

    81 %

    71,943

    84 %



    Consumables and service revenues

    19,950

    19 %

    13,978

    16 %



    Total Net Revenue

    106,074

    100 %

    85,921

    100 %



     

     

     



    Three months ended

    M
    arch 31,

    2023

    2022



    %

    %



    United States

    International

    Total

    United States

    International

    Total

    Revenues by Technology:













    Minimally Invasive

    90

    75

    83

    84

    71

    80

    Hands-Free

    8

    6

    8

    13

    6

    10

    Non-Invasive

    2

    19

    9

    3

    23

    10



    100

    100

    100

    100

    100

    100

     

     

     

    INMODE LTD.

    RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

     INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



     Three months ended

    March 31, 2023

     Three months ended

    March 31, 2022



     

     

    GAAP

     

    Share Based

    Compensation

     

     

    Non-GAAP

     

     

    GAAP

     

    Share Based

    Compensation

     

     

    Non-GAAP



    REVENUES

    106,074

    -

    106,074

    85,921

    -

    85,921



    COST OF REVENUES

    18,254

    (354)

    17,900

    14,772

    (314)

    14,458



    GROSS PROFIT

    87,820

    354

    88,174

    71,149

    314

    71,463



    OPERATING EXPENSES:















    Research and development

    3,102

    (501)

    2,601

    2,815

    (525)

    2,290



    Sales and marketing

    41,713

    (3,038)

    38,675

    30,849

    (1,895)

    28,954



    General and administrative

    2,008

    (316)

    1,692

    2,477

    (360)

    2,117



    TOTAL OPERATING

    EXPENSES

     

    46,823

     

    (3,855)

     

    42,968

     

    36,141

     

    (2,780)

     

    33,361



    INCOME FROM OPERATIONS

    40,997

    4,209

    45,206

    35,008

    3,094

    38,102



    Finance income, net

    3,289

    -

    3,289

    379

    -

    379



    INCOME BEFORE TAXES

    44,286

    4,209

    48,495

    35,387

    3,094

    38,481



    INCOME TAXES

    3,781

    -

    3,781

    4,412

    -

    4,412



    NET INCOME

    40,505

    4,209

    44,714

    30,975

    3,094

    34,069



















    NET INCOME PER SHARE:















    Basic

    0.49



    0.54

    0.37



    0.41



    Diluted

    0.47



    0.52

    0.36



    0.40



    WEIGHTED AVERAGE NUMBER OF

    SHARES OUTSTANDING USED IN 

    COMPUTATION OF NET INCOME

    PER SHARE (in thousands)















    Basic

    83,154



    83,154

    82,973



    82,973



    Diluted

    85,387



    85,878

    85,696



    86,132



     

    Cision View original content:https://www.prnewswire.com/news-releases/inmode-reports-first-quarter-2023-financial-results-quarterly-revenue-of-106-1m-represents-23-5-year-over-year-growth-301812367.html

    SOURCE InMode Ltd.

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:09:10 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:06:52 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mizrahy Moshe

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:08:06 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    3/13/26 7:00:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    2/23/26 7:00:19 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by InMode Ltd.

    S-8 - InMode Ltd. (0001742692) (Filer)

    2/10/26 7:38:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

    4/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Present at the 25th Annual Needham Virtual Healthcare Conference

    YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026. The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 11:00 am Eastern Time on Monday, April 13, and a live webcast of the presentation can be accessed here. InMode will also hold virtual one-on-one investor meetings

    3/24/26 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Announces New Share Repurchase Program

    YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares. In 2025, the Company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs. Despite a challenging macroeconomic environment, the Company continues to generate strong cash fl

    3/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

    4/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

    YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti

    2/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M

    Conference call to be held on Tuesday, February 10, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year of 2025 before the Nasdaq market opens on Tuesday, February 10, 2026. InMode is currently finalizing its financial results for the fourth quarter and full year of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and ot

    1/8/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care